 (Thorax 1996;51:262-266) 
The aerosol cannisters and plastic actuators were masked and placed in identical boxes to blind the treatment to the patient. Each treatiment box was dispensed by a different person from the investigator to make the study double blind. Each of the nine study visits was separated by a washout period of at least three days. Subjects omitted their usual steroid inhaler on each study day and took their bronchodilator inhaler 15 minutes before the study drug in the evening. Mouth rinsing was performed after each two puffs of their study inhaler. Before taking the study drug subjects emptied their bladder and collected all their ovemight urine for 10 hours until the laboratory visit the following morning. No further steroid or bronchodilator inhalers were taken until completion of the laboratory visit.
MEASUREMENTS
The subjects attended the laboratory at 08.00 hours, 10 hours after taking the study drug. A cannula was inserted into an antecubital fossa vein to allow blood sampling, and subjects then rested supine for 30 minutes. After the rest period blood samples were taken for measurement of serum cortisol and plasma adrenocorticotrophic hormone (ACTH) levels. The total volume of the overnight 10 hour urine specimen was measured, with aliquots kept for assay of cortisol levels.
ASSAYS
Serum and urinary cortisol levels were measured using a commercial radioimmunoassay kit (Incstar, Wokingham, Berkshire, UK). The coefficient of variability for analytical imprecision within the assay was 9'4%. The lower limit for the normal reference range of serum cortisol levels in our laboratory is 150 nmol/l. Plasma levels of ACTH were measured using a commercial immunoradiometric assay (Incstar, Wokingham, Berkshire, UK). The coefficient of variability for analytical imprecision within the assay was 3-54%. DATA by multifactorial analysis of variance (MANOVA) using subjects, treatments, and doses as within factors. Where the overall MANOVA was significant, Duncan's multiple range testing with 95% confidence limits was used in order to define where these differences were significant. A probability level of p<005 (two tailed) was considered to be significant for all tests. For the primary comparison between treatments the 95% CI for mean differences were also calculated where a significant difference was detected. For comparison of the proportion of individual cortisol values below the normal reference range the X' test was used. Values are means and 95% confidence intervals are given where the difference is significant. *p<0.05; **p<0.01. The urinary free cortisol (nmol/1 0 hours) results are illustrated in fig 3 and from one inhaled corticosteroid to another versus budesonide (95% would be made at the same dose rather than dividual values for serum at half the dose. Since mouth rinsing was emtwo highest doses showed ployed, it can be concluded that the systemic low the lower limit of the bioactivity of fluticasone is, like budesonide, nmol/l) for fluticasone and mainly due to lung vascular absorption. snide (p<0O005; fig 2) .
It is perhaps not surprising that adrenal sup-500 1tg and 2000 pg sig-pression was only detected at doses above d plasma ACTH levels 1000 jg using early morning serum cortisol ,ith placebo, while bu-and ACTH levels as these are the least sensitive )w significant suppression markers. Nonetheless, using ACTH we found ne produced significantly significant suppression by fluticasone pro-;ma ACTH levels than pionate at single doses of 1500 ,ug and 2000 jtg gtg and 2000 pig. In terms but not with budesonide. Using urinary cortisol )ression versus placebo, excretion, a more sensitive marker, fluticasone duced a greater effect at produced significant suppression at the 500 ,ug dose compared with placebo. In a chronic dosing study reported by Grove et al in normal subjects similar doses of fluticasone propionate dry powder Diskhaler (750 jig, 1500 jig) were compared with budesonide dry powder Turbohaler (800 jig, 1600 jig), each dose being given for one week with mouth rinsing.9 The degree of suppression as assessed by the tetracosactrin response was comparable for both drugs, despite a twofold difference in drug delivered to the lung with the Turbohaler (27% deposition) compared with the Diskhaler (12% deposition).812 The conclusion drawn from this study was that, allowing for the confounding effect of lung deposition for the different dry powder devices, fluticasone propionate would be expected to produce greater adrenal suppression. This is in agreement with our present results which show at least twofold greater systemic bioactivity 
